Cooley advised Candid Therapeutics (Candid), a global clinical-stage biotechnology company advancing a leading portfolio of T-cell engager therapeutics for autoimmune diseases, on its definitive merger agreement with Rallybio Corporation (Nasdaq: RLYB). Upon completion of the merger, the combined company expects to operate under the name Candid Therapeutics, Inc. and trade on Nasdaq under the ticker symbol CDRX.